Chronic administration of XBD173 ameliorates cognitive deficits and neuropathology via 18 kDa translocator protein (TSPO) in a mouse model of Alzheimer’s disease. This evidence concerns the gene TSPO and early-onset autosomal dominant Alzheimer disease.